Intervals between PCV13 and PPSV23 vaccines: Recommendations of the advisory committee on immunization practices (ACIP)

Morbidity and Mortality Weekly Report

Volumn 64, Issue 34, 2015, Pages 944-947

  Kobayashi, Miwako ^a,b   Bennett, Nancy M ^b   Gierke, Ryan ^a   Almendares, Olivia ^a   Moore, Matthew R ^a   Whitney, Cynthia G ^a   Pilishvili, Tamara ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; PNEUMOCOCCUS VACCINE; PREVENAR13; VACCINE;

ADOLESCENT; ADULT; ADVISORY COMMITTEE; AGE; AGED; CHILD; HUMAN; IMMUNIZATION; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PRACTICE GUIDELINE; PRESCHOOL CHILD; RISK FACTOR; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ADVISORY COMMITTEES; AGE FACTORS; AGED; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION SCHEDULE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; UNITED STATES; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84940853464     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: 10.15585/mmwr.mm6434a4     Document Type: Article

References (18)

1. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014;63:822–5.
2. CDC. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816–9.
3. CDC. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013;62:521–4.
4. Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine— recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59(No. RR-11):1–18.
5. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60–64 years of age. Vaccine 2014;32:2364–74.
6. Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and proteinconjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008;198:1019–27.
7. Blum MD, Dagan R, Mendelman PM, et al. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine 2000;18:2359–67.
8. Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years. Clin Infect Dis 2009;49:1318–25.
9. Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013;31:3594–602.
10. Miernyk KM, Butler JC, Bulkow LR, et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55–70 years of age. Clin Infect Dis 2009;49:241–8.
11. Lazarus R, Clutterbuck E, Yu LM, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011;52:736–42.
12. Macintyre CR, Ridda I, Gao Z, et al. A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly. PLoS One 2014;9:e94578.
13. de Roux A, Schmöle-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008;46:1015–23.
14. CDC. Active bacterial core surveilance (ABCs). Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available from: http://www.cdc.gov/abcs/reports-findings/survreports/spneu13.html.
15. Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for US adults: national health interview survey, 2012. Vital Health Stat 10 2014;10:1–161.
16. Centers for Medicare and Medicaid Services. Modifications to Medicare part B coverage of pneumococcal vaccinations. Washington, DC: Department of Health and Human Services, Centers for Medicare and Medicaid Services; 2014. Available at https://www.cms.gov/Outreachand-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM9051.pdf.
17. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001;20:545–53.
18. Lesprit P, Pédrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007;21:2425–34.